Tag Archives: Global

Is There a Global Policy Gap on Cancer?

Eli Lilly thinks so, with a new “back to school” pathway on stakeholder engagement Monday, February 4, is World Cancer Day.  Eli Lilly & Co., one of big Pharma’s biggest, has decided to give the moment its due with the launch of a new policy advocacy initiative to ensure that patients actually benefit from the […]
Posted in Global | Also tagged , , | Leave a comment

Pharma's Promotional Spend: What's the Right Target?

Global consultancy Cegedim has released its latest survey on how and where big Pharma puts its promotional dollar. Pharmaceutical Promotional Spend: Global Trends reports that spending in emerging markets significantly increased last year, while Europe and US declined slightly.  Although overall promotion spending remained flat worldwide at $90 billion, the US still accounts for the […]
Posted in Advertising, Emerging Markets, Europe, Global, Marketing, Meetings, Sales, social media, Strategy, Technology | Also tagged , , , , | Leave a comment

SciClone Pharmaceuticals: Selling Specialty Drugs in China

US-based SciClone Pharmaceuticals has built its business around selling specialty drugs in China. Companies like Sanofi and Pfizer, despite their own in-country resources, have partnered with SciClone and are achieving better returns, according to SciClone CEO Friedhelm Blobel.
Posted in Biotech, compliance, Emerging Markets, Global, healthcare, IP, Legal, Manufacturing, People, pricing, Regulatory, Sales, Strategy | Also tagged , | 1 Comment

Can Emerging Markets Emerge Fast Enough?

The IMS Institute’s annual report on global drug spending predicts a slight rebound in developed markets, despite historically low growth rates. In emerging markets, growth continues to be robust, but is it enough to balance the ongoing stagnancy in Europe and the US?
Posted in Emerging Markets, Europe, Global, leadership, Market Access, pricing, Strategy | Also tagged , , , , | Leave a comment

Fixing Innovation: Lilly's CEO Says Why, and How

Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, healthcare, IP, leadership, Legal, Market Access, Meetings, People, pricing, R&D, Regulatory, Safety, Strategy, Technology | Also tagged , , , , , , , , , , , , | 1 Comment
  • Categories

  • Meta